EMTC-M Stock Overview
Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of therapeutic medical systems in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Elbit Medical Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.16 |
| 52 Week High | ₪0.62 |
| 52 Week Low | ₪0.15 |
| Beta | 0.27 |
| 1 Month Change | -31.60% |
| 3 Month Change | -39.46% |
| 1 Year Change | -73.67% |
| 3 Year Change | -89.46% |
| 5 Year Change | -83.30% |
| Change since IPO | -94.94% |
Recent News & Updates
Shareholder Returns
| EMTC-M | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | -2.5% | -0.3% | 2.9% |
| 1Y | -73.7% | 6.3% | 10.8% |
Return vs Industry: EMTC-M underperformed the IL Medical Equipment industry which returned 6.3% over the past year.
Return vs Market: EMTC-M underperformed the IL Market which returned 10.8% over the past year.
Price Volatility
| EMTC-M volatility | |
|---|---|
| EMTC-M Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 4.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: EMTC-M's share price has been volatile over the past 3 months.
Volatility Over Time: EMTC-M's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 664 | Ron Hadassi | n/a |
Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of therapeutic medical systems in the United States, Europe, and internationally. The company is developing a magnetic resonance imaging guided focused ultrasound treatment equipment to address various oncology and gynecology indications, as well as neurological disorders and tumors. It is also involved in the study and development of medical products based on stem cells originating primarily from the umbilical cord blood that are used for bone marrow transplants in the patients of leukemia or cancer of lymph nodes, non-malignant blood diseases, and metabolic genetic disorders.
Elbit Medical Technologies Ltd Fundamentals Summary
| EMTC-M fundamental statistics | |
|---|---|
| Market cap | ₪14.33m |
| Earnings (TTM) | -₪67.55m |
| Revenue (TTM) | ₪1.32m |
10.8x
P/S Ratio-0.2x
P/E RatioIs EMTC-M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMTC-M income statement (TTM) | |
|---|---|
| Revenue | US$348.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$348.00k |
| Other Expenses | US$18.14m |
| Earnings | -US$17.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,113.22% |
| Debt/Equity Ratio | 0% |
How did EMTC-M perform over the long term?
See historical performance and comparison